(MBOT) Microbot Medical - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 115m USD | Total Return: -33% in 12m
Avg Turnover: 2.59M
Qual. Beats: 1
Qual. Beats: -1
Warnings
Share dilution 116.1% YoY
High Debt while negative Cash Flow
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Microbot Medical Inc. (MBOT) is a Massachusetts-based medical device developer specializing in robotic systems for minimally invasive endoluminal surgery. The company’s primary focus is the LIBERTY system, an endovascular robotic platform designed to navigate microcatheters and guidewires through the human vasculature for cardiovascular and neurovascular procedures. The firm also holds intellectual property for NovaCross, a revascularization technology utilizing an anchoring mechanism.
The medical robotics sector seeks to reduce physician radiation exposure and improve precision compared to manual catheterization. MBOT operates under a research and development business model, utilizing strategic collaborations with institutions like Corewell Health and Emory University to advance autonomous capabilities in endovascular procedures.
For more detailed insights, you may wish to explore the data available on ValueRay.
- FDA clearance status for LIBERTY robotic system dictates near-term commercial viability
- Clinical trial results for LIBERTY system drive investor sentiment and valuation
- Strategic collaborations with health systems influence path to market adoption
- Cash burn rate and potential equity dilution impact long-term capital structure
- Intellectual property protection for NovaCross technology secures competitive market positioning
| Net Income: -14.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA 10.42 > 1.0 |
| NWC/Revenue: 69.7k% < 20% (prev 34.2k%; Δ 35.4k% < -1%) |
| CFO/TA -0.20 > 3% & CFO -15.2m > Net Income -14.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.2m) vs 12m ago 294.6% < -2% |
| Gross Margin: -28.57% > 18% (prev 0.07%; Δ -2.86k% > 0.5%) |
| Asset Turnover: 0.19% > 50% (prev 0.27%; Δ -0.08% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 76.5m - Total Current Liabilities 3.39m) / Total Assets 78.1m |
| B: -1.38 (Retained Earnings -107.8m / Total Assets 78.1m) |
| C: -0.29 (EBIT TTM -15.8m / Avg Total Assets 54.5m) |
| D: -27.03 (Book Value of Equity -107.1m / Total Liabilities 3.96m) |
| Altman-Z'' = -28.69 = D |
As of May 27, 2026, the stock is trading at USD 1.81 with a total of 2,339,539 shares traded.
Over the past week, the price has changed by +1.69%,
over one month by -16.59%,
over three months by -29.30% and
over the past year by -32.96%.
Microbot Medical has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy MBOT.
- StrongBuy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.5 | 369.6% |
P/E Forward = 31.746
P/S = 1093.8268
P/B = 1.5499
P/EG = 0.6952
Revenue TTM = 105k USD
EBIT TTM = -15.8m USD
EBITDA TTM = -15.8m USD
Long Term Debt = 574k USD (estimated: total debt 898k - short term 324k)
Short Term Debt = 324k USD (from shortTermDebt, last quarter)
Debt = 898k USD (from shortLongTermDebtTotal, last quarter) (leases 898k already included)
Net Debt = -71.6m USD (calculated: Debt 898k - CCE 72.5m)
Enterprise Value = 43.2m USD (114.9m + Debt 898k - CCE 72.5m)
Interest Coverage Ratio = unknown (Ebit TTM -15.8m / Interest Expense TTM 0.0)
EV/FCF = -2.81x (Enterprise Value 43.2m / FCF TTM -15.4m)
FCF Yield = -35.56% (FCF TTM -15.4m / Enterprise Value 43.2m)
FCF Margin = -14.6k% (FCF TTM -15.4m / Revenue TTM 105k)
Net Margin = -13.5k% (Net Income TTM -14.2m / Revenue TTM 105k)
Gross Margin = -28.57% ((Revenue TTM 105k - Cost of Revenue TTM 135k) / Revenue TTM)
Gross Margin QoQ = 1.90% (prev none%)
Tobins Q-Ratio = 0.55 (Enterprise Value 43.2m / Total Assets 78.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 898k)
Taxrate = 21.0% (US default 21%)
NOPAT = -12.5m (EBIT -15.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.59 (Total Current Assets 76.5m / Total Current Liabilities 3.39m)
Debt / Equity = 0.01 (Debt 898k / totalStockholderEquity, last quarter 74.1m)
Debt / EBITDA = 4.54 (negative EBITDA) (Net Debt -71.6m / EBITDA -15.8m)
Debt / FCF = 4.66 (negative FCF - burning cash) (Net Debt -71.6m / FCF TTM -15.4m)
Total Stockholder Equity = 65.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.09% (Net Income -14.2m / Total Assets 78.1m)
RoE = -8.22% (Net Income TTM -14.2m / Total Stockholder Equity 172.8m)
RoCE = -9.12% (EBIT -15.8m / Capital Employed (Equity 172.8m + L.T.Debt 574k))
RoIC = -499.3% (out of range, set to none) (NOPAT -12.5m / Invested Capital 2.50m)
WACC = 7.95% (E(114.9m)/V(115.7m) * Re(8.01%) + D(898k)/V(115.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 132.9%
[DCF] Fair Price = unknown (Cash Flow -15.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.96 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -1.79 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.09 | Chg30d=-12.50% | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.08 | Chg30d=+0.00% | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=-0.31 | Chg30d=+3.13% | Revisions=N/A | GrowthEPS=-6.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.28 | Chg30d=+15.15% | Revisions=+20% | GrowthEPS=+9.7% | GrowthRev=+200.0%